Cipher Pharmaceuticals Inc.
CPH.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -9.82% | 4.04% | 3.35% | 23.75% | 152.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.82% | 4.04% | 3.35% | 23.75% | 152.28% |
| Cost of Revenue | -5.20% | -23.31% | -55.08% | 19.19% | 125.86% |
| Gross Profit | -10.88% | 12.66% | 48.12% | 24.82% | 159.24% |
| SG&A Expenses | -22.15% | -39.98% | -24.05% | -19.35% | 210.17% |
| Depreciation & Amortization | -1.22% | -0.82% | 19.52% | -6.65% | 518.84% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.60% | -27.61% | -32.17% | -7.54% | 209.02% |
| Operating Income | -5.15% | 126.15% | 1,225.15% | 165.99% | 92.78% |
| Income Before Tax | -43.11% | 162.27% | 261.63% | 1,206.13% | 154.67% |
| Income Tax Expenses | -172.07% | -64.72% | -40.34% | -2,990.70% | 206.67% |
| Earnings from Continuing Operations | -31.90% | 134.87% | 298.06% | 1,843.82% | 96.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.90% | 134.87% | 298.06% | 1,843.82% | 96.76% |
| EBIT | -5.15% | 126.15% | 1,225.15% | 165.99% | 92.78% |
| EBITDA | -5.31% | 70.51% | 256.01% | 78.37% | 135.96% |
| EPS Basic | -30.64% | 134.78% | 300.00% | 1,835.71% | 83.41% |
| Normalized Basic EPS | -37.94% | 142.77% | 343.00% | 115.47% | 113.38% |
| EPS Diluted | -31.82% | 140.00% | 289.23% | 2,000.00% | 83.33% |
| Normalized Diluted EPS | -37.81% | 146.36% | 338.27% | 114.69% | 112.08% |
| Average Basic Shares Outstanding | -1.81% | 0.00% | -0.49% | 0.80% | 7.28% |
| Average Diluted Shares Outstanding | -1.96% | -1.52% | 1.47% | 0.99% | 7.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |